Abstract
A growing body of literature indicates that activation of cannabinoid receptors may exert beneficial effects on gastrointestinal inflammation and visceral hypersensitivity. The present study aimed to immunohistochemically investigate the distribution of the canonical cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) and the putative cannabinoid receptors G protein-coupled receptor 55 (GPR55), nuclear peroxisome proliferator-activated receptor alpha (PPARα), transient receptor potential ankyrin 1 (TRPA1), and serotonin receptor 5-HT1a 5-HT1aR) in tissue samples of the gastrointestinal tract of the cat. CB1R-immunoreactivity (CB1R-IR) was observed in gastric epithelial cells, intestinal enteroendocrine cells (EECs) and goblet cells, lamina propria mast cells (MCs), and enteric neurons. CB2R-IR was expressed by EECs, enterocytes, and macrophages. GPR55-IR was expressed by EECs, macrophages, immunocytes, and MP neurons. PPARα-IR was expressed by immunocytes, smooth muscle cells, and enteroglial cells. TRPA1-IR was expressed by enteric neurons and intestinal goblet cells. 5-HT1a receptor-IR was expressed by gastrointestinal epithelial cells and gastric smooth muscle cells. Cannabinoid receptors showed a wide distribution in the feline gastrointestinal tract layers. Although not yet confirmed/supported by functional evidences, the present research might represent an anatomical substrate potentially useful to support, in feline species, the therapeutic use of cannabinoids during gastrointestinal inflammatory diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440–452. https://doi.org/10.1038/nri2782
Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK (2017) Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci USA 114:5005–5010. https://doi.org/10.1073/pnas.1612177114
Adami M, Frati P, Bertini S, Kulkarni-Narla A, Brown DR, De Caro G, Coruzzi G, Soldani G (2002) Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 135:1598–1606. https://doi.org/10.1038/sj.bjp.0704625
Ambrosino P, Soldovieri MV, Russo C, Taglialatela M (2013) Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168:1430–1444. https://doi.org/10.1111/bph.12029
Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H, Takeuchi T (2010) PPARα contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10:1261–1267. https://doi.org/10.1016/j.intimp.2010.07.007
Azuma YT, Nishiyama K, Morioka A, Nakajima H, Takeuchi T (2011) Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium-mediated desensitisation of contractile machinery. Pharmacology 88:65–71. https://doi.org/10.1159/000329418
Bado A, Durieux C, Moizo L, Roques BP, Lewin MJ (1991) Cholecystokinin-A receptor mediation of food intake in cats. Am J Physiol 260:693–697. https://doi.org/10.1152/ajpregu.1991.260.4.R693
Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R, Blattermann S, Kostenis E, Brown AJ, Heinemann A, Waldhoer M (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21:1452–1469. https://doi.org/10.1038/cr.2011.60
Bednarska O, Walter SA, Casado-Bedmar M, Ström M, Salvo-Romero E, Vicario M, Mayer EA, Keita ÅV (2017) Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology 153:948–960. https://doi.org/10.1053/j.gastro.2017.06.051
Bischoff SC, Krämer S (2007) Human mast cells, bacteria, and intestinal immunity. Immunol Rev 217:329–337. https://doi.org/10.1111/j.1600-065X.2007.00523.x
Boeckxstaens G (2015) Mast cells and inflammatory bowel disease. Curr Opin Pharmacol 25:45–49. https://doi.org/10.1016/j.coph.2015.11.005
Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P, Di Marzo V, Izzo AA (2015) Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol 172:142–158. https://doi.org/10.1111/bph.12907
Brown AJ, Ueno S, Suen K, Dowell SJ, Wise A (2005) Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. In: Brian T (ed). Symposium on the Cannabinoids. International Cannabinoid Research Society, Burlington, VT, pp 24–27
Cani PD, Everard A, Duparc T (2013) Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol 13:935–940. https://doi.org/10.1016/j.coph.2013.09.008
Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, Izzo AA (2008) Cannabidiol, extracted from Cannabissativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154:1001–1008. https://doi.org/10.1038/bjp.2008.177
Chiocchetti R, Giancola F, Mazzoni M, Sorteni C, Romagnoli N, Pietra M (2015) Excitatory and inhibitory enteric innervation of horse lower esophageal sphincter. Histochem Cell Biol 143:625–635. https://doi.org/10.1007/s00418-014-1306-y
Chiurchiù V, Lanuti M, De Bardi M, Battistini L, Maccarrone M (2015) The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 27:153–160. https://doi.org/10.1093/intimm/dxu097
Cho HJ, Callaghan B, Bron R, Bravo DM, Furness JB (2014) Identification of enteroendocrine cells that express TRPA1 channels in the mouse intestine. Cell Tissue Res 356:77–82. https://doi.org/10.1007/s00441-013-1780-x
Cirillo C, Sarnelli G, Turco F, Mango A, Grosso M, Aprea G, Masone S, Cuomo R (2011) Proinflammatory stimuli activates human-derived enteroglial cells and induces autocrine nitric oxide production. Neurogastroenterol Motil 23:e372–e382. https://doi.org/10.1111/j.1365-2982.2011.01748.x
Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE (2017) Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin Sci 131:2611–2626. https://doi.org/10.1042/CS20171288
Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S (2002) Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448:410–422. https://doi.org/10.1002/cne.10270
Cremon C, Stanghellini V, Barbaro MR, Cogliandro RF, Bellacosa L, Santos J, Vicario M, Pigrau M, Alonso Cotoner C, Lobo B, Azpiroz F, Bruley des Varannes S, Neunlist M, DeFilippis D, Iuvone T, Petrosino S, Di Marzo V, Barbara G (2017) Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther 45:909–922. https://doi.org/10.1111/apt.14014
Darmon M, Langlois X, Suffisseau L, Fattaccini CM, Hamon M (1998) Differential membrane targeting and pharmacological characterization of chimeras of rat serotonin 5-HT1A and 5-HT1B receptors expressed in epithelial LLC-PK1 cells. J Neurochem 71:2294–2303. https://doi.org/10.1046/j.1471-4159.1998.71062294.x
Di Patrizio NV (2016) Endocannabinoids in the gut. Cannabis Cannabinoid Res 1:67–77. https://doi.org/10.1089/can.2016.0001
Di Carlo G, Izzo AA (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 12:39–49. https://doi.org/10.1517/13543784.12.1.39
Di Marzo V, Izzo AA (2006) Endocannabinoid overactivity and intestinal inflammation. Gut 55:1373–1376. https://doi.org/10.1136/gut.2005.090472
Di Marzo V, Piscitelli F (2011) Gut feelings about the endocannabinoid system. Neurogastroenterol Motil 23:391–398. https://doi.org/10.1111/j.1365-2982.2011.01689.x
Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fat Acids 66:377–391. https://doi.org/10.1054/plef.2001.0349
Duncan M, Davison JS, Sharkey KA (2005a) Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22:667–683. https://doi.org/10.1111/j.1365-2036.2005.02648.x
Duncan M, Ho W, Shariat N, Pittman QJ, Mackie K, Patel KD, Sharkey KA (2005b) Distribution of the CB2 receptor in enteric nerves of the rat ileum. In: Symposium on the Cannabinoids, Burlington, VT, International Cannabinoid Research Society, p 159
Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, Patel KD, Pittman QJ, Sharkey KA (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295:G78–G87. https://doi.org/10.1152/ajpgi.90285.2008
Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195–4202. https://doi.org/10.1210/endo.142.10.8458
Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, Cuomo R, Sarnelli G, Steardo L (2014) Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 63:1300–1312. https://doi.org/10.1136/gutjnl-2013-305005
Fabisiak A, Fichna J (2017) Cannabinoids as gastrointestinal anti-inflammatory drugs. Neurogastroenterol Motil 29:e13038. https://doi.org/10.1111/nmo.13038
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376–3380. https://doi.org/10.1073/pnas.92.8.3376
Farquhar-Smith W, Jaggar S, Rice A (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97:11–21. https://doi.org/10.1016/s0304-3959(01)00419-5
Gabrielsson L, Mattsson S, Fowler CJ (2016) Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol 82:932–942. https://doi.org/10.1111/bcp.13020
Galiazzo G, Giancola F, Stanzani A, Fracassi F, Bernardini C, Forni M, Pietra M, Chiocchetti R (2018) Localization of cannabinoid receptors CB1, CB2, GPR55 and PPARα in the canine gastrointestinal tract. Histochem Cell Biol 150:187–205. https://doi.org/10.1007/s00418-018-1684-7
Giancola F, Fracassi F, Gallucci A, Sadeghinezhad J, Polidoro G, Zini E, Asti M, Chiocchetti R (2016) Quantification of nitrergic neurons in the myenteric plexus of gastric antrum and ileum of healthy and diabetic dogs. Auton Neurosci 197:25–33. https://doi.org/10.1016/j.autneu.2016.04.004
Goyal H, Singla U, Gupta U, May E (2017) Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol 29:135–143. https://doi.org/10.1097/MEG.0000000000000779
Grill M, Hasenoehrl C, Kienzl M, Kargl J, Schicho R (2019) Cellular localization and regulation of receptors and enzymes of the endocannabinoid system in intestinal and systemic inflammation. Histochem Cell Biol 151:5–20. https://doi.org/10.1007/s00418-018-1719-0
Gruden G, Barutta F, Kunos G, Pacher P (2016) Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 173:1116–1127. https://doi.org/10.1111/bph.13226
Gyires K, Zádori ZS (2016) Role of cannabinoids in gastrointestinal mucosal defense and inflammation. Curr Neuropharmacol 14:935–951. https://doi.org/10.2174/1570159x14666160303110150
Harvey BS, Nicotra LL, Vu M, Smid SD (2013) Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine 63:209–217. https://doi.org/10.1016/j.cyto.2013.04.032
Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, Blank U, Nilsson G, Maurer M (2014) Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 134:530–544. https://doi.org/10.1016/j.jaci.2014.03.007
Hornby PJ, Prouty SM (2004) Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 141:1335–1345. https://doi.org/10.1038/sj.bjp.0705783
Hu SS, Mackie K (2015) Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol 231:59–93. https://doi.org/10.1007/978-3-319-20825-1_3
Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, Stephens GJ (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5:1131–1141. https://doi.org/10.1021/cn5000524
Iannotti FA, Di Marzo V, Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62:107–128. https://doi.org/10.1016/j.plipres.2016.02.002
Ihenetu K, Molleman A, Parsons ME, Whelan CJ (2003) Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458:207–215. https://doi.org/10.1016/S0014-2999(02)02698-5
Izzo AA (2004) Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142:1201–1202. https://doi.org/10.1038/sj.bjp.0705890
Izzo AA, Sharkey KA (2010) Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126:21–38. https://doi.org/10.1016/j.pharmthera.2009.12.005
Jaggar SI, Sellaturay S, Rice A (1998) The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 253:123–126. https://doi.org/10.1016/S0304-3940(98)00621-1
Karwad MA, Couch DG, Theophilidou E, Sarmad S, Barrett DA, Larvin M, Wright KL, Lund JN, O'Sullivan SE (2017) The role of CB1 in intestinal permeability and inflammation. FASEB J 31:3267–3277. https://doi.org/10.1096/fj.201601346R
Ke P, Shao BZ, Xu ZQ, Wei W, Han BZ, Chen XW, Su DF, Liu C (2016) Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages. PLoS ONE 11:e0155076. https://doi.org/10.1371/journal.pone.0155076
Kirchgessner AL, Liu MT, Raymond JR, Gershon MD (1996) Identification of cells that express 5-hydroxytryptamine1A receptors in the nervous systems of the bowel and pancreas. J Comp Neurol 364:439–455. https://doi.org/10.1002/(SICI)1096-9861(19960115)364:3%3c439:AID-CNE5%3e3.0.CO;2-5
Kleinschmidt S, Harder J, Nolte I, Marsilio S, Hewicker-Trautwein M (2010) Phenotypical characterization, distribution and quantification of different mast cell subtypes in transmural biopsies from the gastrointestinal tract of cats with inflammatory bowel disease. Vet Immunol Immunopathol 137:190–200. https://doi.org/10.1016/j.vetimm.2010.05.005
Kulkarni-Narla A, Brown DR (2000) Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302:73–80. https://doi.org/10.1007/s004410000261
Langlois X, El Mestikawy S, Arpin M, Triller A, Hamon M, Darmon M (1996) Differential addressing of 5-HT1A and 5-HT1B receptors in transfected LLC-PK1 epithelial cells: a model of receptor targeting in neurons. Neuroscience 74:297–302. https://doi.org/10.1016/0306-4522(96)00234-5
Lanuti M, Talamonti E, Maccarrone M, Chiurchiù V (2015) Correction: activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages. PLoS ONE 10:e0131850. https://doi.org/10.1371/journal.pone.0131850
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699–2704. https://doi.org/10.1073/pnas.0711278105
Laun AS, Song ZH (2017) GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun 490:17–21. https://doi.org/10.1016/j.bbrc.2017.05.165
Laun AS, Shrader SH, Brown KJ, Song ZH (2019) GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin 40:300–308. https://doi.org/10.1038/s41401-018-0031-9
Lee Y, Jo J, Chung HY, Pothoulakis C, Im E (2016) Endocannabinoids in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 311:G655–G666. https://doi.org/10.1152/ajpgi.00294.2015
Li C, Bowe JE, Jones PM, Persaud SJ (2010) Expression and function of cannabinoid receptors in mouse islets. Islets 2:293–302. https://doi.org/10.4161/isl.2.5.12729
Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M (2013) A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology 71:255–263. https://doi.org/10.1016/j.neuropharm.2013.03.029
Ligresti A, De Petrocellis L, Di Marzo V (2016) From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev 96:1593–1659. https://doi.org/10.1152/physrev.00002.2016
Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M (2011) A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 23:862–e342. https://doi.org/10.1111/j.1365-2982.2011.01742.x
Liu YA, Chung YC, Pan ST, Shen MY, Hou YC, Peng SJ, Pasricha PJ, Tang SC (2013) 3-D imaging, illustration, and quantitation of enteric glial network in transparent human colon mucosa. Neurogastroenterol Motil 25:e324–e338. https://doi.org/10.1111/nmo.12115
Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ (2016) GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes Metab 18:1263–1273. https://doi.org/10.1111/dom.12780
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005a) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19. https://doi.org/10.1124/mol.104.006353
Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D (2005b) The search for the palmitoylethanolamide receptor. Life Sci 77:1685–1698. https://doi.org/10.1016/j.lfs.2005.05.012
Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, Andreu M (2009) Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS ONE 4:e6893. https://doi.org/10.1371/journal.pone.0006893
Marshall JS (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4:787–799. https://doi.org/10.1038/nri1460
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007) Cannabidiol-recent advances. Chem Biodivers 4:1678–1692. https://doi.org/10.1002/cbdv.200790147
Miragliotta V, Ricci PL, Albanese F, Pirone A, Tognotti D, Abramo F (2018) Cannabinoid receptor types 1 and 2 and peroxisome proliferator-activated receptor-α: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis. Vet Dermatol 29:316–e111. https://doi.org/10.1111/vde.12658
Morales P, Hurst DP, Reggio PH (2017) Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod 103:103–131. https://doi.org/10.1007/978-3-319-45541-9_4
Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, Evans ML, Gribble FM, Reimann F (2012) Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 55:3094–3103. https://doi.org/10.1007/s00125-012-2663-5
Ochoa-Cortes F, Turco F, Linan-Rico A, Soghomonyan S, Whitaker E, Wehner S, Cuomo R, Christofi FL (2016) Enteric glial cells: a new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases. Inflamm Bowel Dis 22:433–449. https://doi.org/10.1097/MIB.0000000000000667
Owyang C, Heldsinger A (2011) Vagal control of satiety and hormonal regulation of appetite. J Neurogastroenterol Motil 17:338–348. https://doi.org/10.5056/jnm.2011.17.4.338
Pazos MR, Tolón RM, Benito C, Rodríguez CF, Gorgojo JJ, Nevado M, Alvarez M, Arias F, Almodóvar F, Fernández MT, Lledó JL, González S, Fernández-Ruiz JJ, Romero J (2008) Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. J Histochem Cytochem 56:511–516. https://doi.org/10.1369/jhc.2008.950741
Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48:859–867. https://doi.org/10.1136/gut.48.6.859
Pertwee RG (2015) Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol 231:1–37. https://doi.org/10.1007/978-3-319-20825-1_1
Petrosino S, Di Marzo V (2016) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 174:1349–1365. https://doi.org/10.1111/bph.13580
Pierezan F, Mansell J, Ambrus A, Rodrigues Hoffmann A (2014) Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol 151:347–351. https://doi.org/10.1016/j.jcpa.2014.07.003
Poole DP, Pelayo JC, Cattaruzza F, Kuo Y-M, Gai G, Chiu JV, Bron R, Furness JB, Grady EF, Bunnett NW (2011) Transient receptor potential ankyrin 1 is expressed by inhibitory motoneurons of the mouse intestine. Gastroenterology 141(565–575):575.e1–4. https://doi.org/10.1053/j.gastro.2011.04.049
Re G, Barbero R, Miolo A, Di Marzo V (2007) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173:21–30. https://doi.org/10.1016/j.tvjl.2005.10.003
Rigano D, Sirignano C, Taglialatela-Scafati O (2017) The potential of natural products for targeting PPARα. Acta Pharm Sin B 7:427–438. https://doi.org/10.1016/j.apsb.2017.05.005
Ross RA (2011) l-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 32:265–269. https://doi.org/10.1016/j.tips.2011.01.005
Russo EB (2018) Cannabis therapeutics and the future of neurology. Front Integr Neurosci 12:51. https://doi.org/10.3389/fnint.2018.00051
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101. https://doi.org/10.1038/sj.bjp.0707460
Sadeghinezhad J, Sorteni C, Di Guardo G, D'Agostino C, Agrimi U, Nonno R, Chiocchetti R (2013) Neurochemistry of myenteric plexus neurons of bank vole (Myodesglareolus) ileum. Res Vet Sci 95:846–853. https://doi.org/10.1016/j.rvsc.2013.07.028
Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170:4953–4962. https://doi.org/10.4049/jimmunol.170.10.4953
Schubert ML (2016) Gastric acid secretion. Curr Opin Gastroenterol 32:452–460. https://doi.org/10.1097/MOG.0000000000000308
Sharkey KA (2015) Emerging roles for enteric glia in gastrointestinal disorders. J Clin Investig 125:918–925. https://doi.org/10.1172/JCI76303
Sharkey KA, Wiley JW (2016) Getting into the weed: the role of the endocannabinoid system in the brain–gut axis. Gastroenterology 151:252–266. https://doi.org/10.1053/j.gastro.2016.04.015
Shea-Donohue T, Stiltz J, Zhao A, Notari L (2010) Mast cells. Curr Gastroenterol Rep 12:349–357. https://doi.org/10.1007/s11894-010-0132-1
Stančić A, Jandl K, Hasenöhrl C, Reichmann F, Marsche G, Schuligoi R, Heinemann A, Storr M, Schicho R (2015) The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil 27:1432–1445. https://doi.org/10.1111/nmo.12639
Storr MA, Sharkey KA (2007) The endocannabinoid system and gut–brain signalling. Curr Opin Pharmacol 7:575–582. https://doi.org/10.1016/j.coph.2007.08.008
Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, Allescher HD (2004) Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 286:G110–G117. https://doi.org/10.1152/ajpgi.00148.2003
Svensson M, Chen P, Hammarfjord O (2010) Dendritic cell regulation by cannabinoid-based drugs. Pharmaceuticals 3:2733–2750. https://doi.org/10.3390/ph3082733
Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP (2012) Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS ONE 7:e42373. https://doi.org/10.1371/journal.pone.0042373
Taylor L, Christou I, Kapellos TS, Buchan A, Brodermann MH, Gianella-Borradori M, Russel A, Igbal AJ, Greaves DR (2015) Primary macrophage chemotaxis induced by cannabinoid receptor 2 agonists occurs independently of the CB2 receptor. Sci Rep 5:10682. https://doi.org/10.1038/srep10682
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613. https://doi.org/10.1038/sj.bjp.0707133
Tudurí E, Imbernon M, Hernández-Bautista R, Tojo M, Fernø J, Diéguez C, Nogueiras R (2017) GPR55: a new promising target for metabolism? J Mol Endocrinol 58:R191–R202. https://doi.org/10.1530/JME-16-0253
Uranga JA, Vera G, Abalo R (2018) Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol 157:134–147. https://doi.org/10.1016/j.bcp.2018.07.048
Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121:767–774. https://doi.org/10.1053/gast.2001.28466
Walls AF, He S, Buckley MG, McEuen AR (2001) Roles of the mast cell and basophil in asthma. Clin Exp Allergy 1:68–72. https://doi.org/10.1046/j.1472-9725.2001.00009.x
Wouters MM, Vicario M, Santos J (2016) The role of mast cells in functional GI disorders. Gut 65:155–168. https://doi.org/10.1136/gutjnl-2015-309151
Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S (2005) Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129:437–453. https://doi.org/10.1053/j.gastro.2005.05.026
Wright KL, Duncan M, Sharkey KA (2008) Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153:263–270. https://doi.org/10.1038/sj.bjp.0707486
Yang YY, Hsieh SL, Lee PC, Yeh YC, Lee KC, Hsieh YC, Wang YW, Lee TY, Huang YH, Chan CC, Lin HC (2014) Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites. J Hepatol 61:1004–1013. https://doi.org/10.1016/j.jhep.2014.05.049
Zhang L, Song J, Hou X (2016) Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil 22:181–192. https://doi.org/10.5056/jnm15137
Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, Braun J (2006) Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58:714–725. https://doi.org/10.1007/s00251-006-0138-x
Acknowledgements
We thank Prof. Catia Sternini (UCLA, Los Angeles) for the generous gift of the anti-GAS/CCK antibody used for this study. We thank Prof. Peter F. Moore (University of California, Davis, CA) for the generous gift of the anti-CD3 antibody used in this study. The excellent technical assistance provided by Prof. Monica Forni, Dr. Chiara Bernardini, and Dr. Silvia Fiegna is gratefully acknowledged.
Funding
This research received a grant from Formula Swiss AG, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Stanzani, A., Galiazzo, G., Giancola, F. et al. Localization of cannabinoid and cannabinoid related receptors in the cat gastrointestinal tract. Histochem Cell Biol 153, 339–356 (2020). https://doi.org/10.1007/s00418-020-01854-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-020-01854-0